Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Leticia Mayor-López"'
Autor:
Leticia Mayor-López, Elena Tristante, Mar Carballo-Santana, Estefanía Carrasco-García, Silvina Grasso, Pilar García-Morales, Miguel Saceda, Juan Luján, José García-Solano, Fernando Carballo, Carlos de Torre, Isabel Martínez-Lacaci, PhD
Publikováno v:
Translational Oncology, Vol 7, Iss 5, Pp 590-604 (2014)
The use of heat shock protein 90 (Hsp90) inhibitors is an attractive antineoplastic therapy. We wanted to compare the effects of the benzoquinone 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) and the novel isoxazole resorcinol–based
Externí odkaz:
https://doaj.org/article/9569dd5d0753487a8b725daec68fab77
Autor:
Silvina Grasso, Elena Tristante, Miguel Saceda, Pablo Carbonell, Leticia Mayor-López, Mar Carballo-Santana, Estefanía Carrasco-García, Lourdes Rocamora-Reverte, Pilar García-Morales, Fernando Carballo, José A. Ferragut, Isabel Martínez-Lacaci
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 10, Pp 845-860 (2014)
Selumetinib (AZD6244, ARRY-142886) is a MEK1/2 inhibitor that has gained interest as an anti-tumour agent. We have determined the degree of sensitivity/resistance to Selumetinib in a panel of colorectal cancer cell lines using cell proliferation and
Externí odkaz:
https://doaj.org/article/41f0fc5470f7441089abe5f2f1f656c0
Autor:
Estefania Carrasco-Garcia, Isabel Martinez-Lacaci, Leticia Mayor-López, Elena Tristante, Mar Carballo-Santana, Pilar García-Morales, Maria Paz Ventero Martin, Maria Fuentes-Baile, Álvaro Rodriguez-Lescure, Miguel Saceda
Publikováno v:
Cells, Vol 7, Iss 9, p 131 (2018)
Glioblastomas are highly resistant to radiation and chemotherapy. Currently, there are no effective therapies for this type of tumor. Signaling mechanisms initiated by PDGFR and IGF-1R are important in glioblastoma, and inhibition of the signal trans
Externí odkaz:
https://doaj.org/article/a7bcf726b8184a67940e97c04e3496ca
Autor:
Maria Fuentes-Baile, Estefania Carrasco-Garcia, Elena Tristante, P. Garcia-Morales, Álvaro Rodríguez-Lescure, Maria Paz Ventero Martin, Mar Carballo-Santana, Miguel Saceda, Isabel Martínez-Lacaci, Leticia Mayor-López
Publikováno v:
Cells
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Volume 7
Issue 9
Cells, Vol 7, Iss 9, p 131 (2018)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Volume 7
Issue 9
Cells, Vol 7, Iss 9, p 131 (2018)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Glioblastomas are highly resistant to radiation and chemotherapy. Currently, there are no effective therapies for this type of tumor. Signaling mechanisms initiated by PDGFR and IGF-1R are important in glioblastoma, and inhibition of the signal trans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5ac39a02e13094ac81112169c88f27a
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2442
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2442
Autor:
Elena Tristante, Juan Luján, José García-Solano, P. Garcia-Morales, Leticia Mayor-López, Estefania Carrasco-Garcia, Silvina Grasso, Carlos de Torre, Fernando Carballo, Mar Carballo-Santana, Isabel Martínez-Lacaci, Miguel Saceda
Publikováno v:
Translational Oncology, Vol 7, Iss 5, Pp 590-604 (2014)
The use of heat shock protein 90 (Hsp90) inhibitors is an attractive antineoplastic therapy. We wanted to compare the effects of the benzoquinone 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) and the novel isoxazole resorcinol–based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e60fd2b6579a06270beb7f06546a1b3
https://doi.org/10.1016/j.tranon.2014.08.001
https://doi.org/10.1016/j.tranon.2014.08.001
Autor:
Silvina Grasso, José A. Ferragut, Elena Tristante, Isabel Martínez-Lacaci, Leticia Mayor-López, Estefania Carrasco-Garcia, Pilar Garcia-Morales, Lourdes Rocamora-Reverte, Miguel Saceda, Ángeles Gómez-Martínez, M. Piedad Menéndez-Gutiérrez
Publikováno v:
Apoptosis and Medicine
Life and death are essential parts of the natural cycle of all multicellular organisms. In metazoans, somatic cells divide normally during the process known as mitosis. Cell proliferation is tightly controlled, according to the organism needs. An inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::135741990ed143a521c822002f1351f5
https://doi.org/10.5772/51285
https://doi.org/10.5772/51285
Autor:
Mar Carballo-Santana, Leticia Mayor-López, Elena Tristante, P. Garcia-Morales, M. Fuentes-Baile, Miguel Saceda, Estefania Carrasco-Garcia
Publikováno v:
European Journal of Cancer. 51:S50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8e4ced529533bd3186887dfa1c74a64
https://doi.org/10.1016/s0959-8049(16)30156-3
https://doi.org/10.1016/s0959-8049(16)30156-3
Autor:
Isabel Martínez-Lacaci, P. Garcia-Morales, Estefania Carrasco-Garcia, Fernando Carballo, E. Tristante-Barrenechea, Miguel Saceda, C. De Torre, Leticia Mayor-López
Publikováno v:
European Journal of Cancer. 48:S231-S232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::034ddcc19eb03fa4f31179e5fb9ec04c
https://doi.org/10.1016/s0959-8049(12)71581-2
https://doi.org/10.1016/s0959-8049(12)71581-2
Autor:
Fernando Carballo, A. Torroba, E. Tristante-Barrenechea, R. Martínez-Marín, Isabel Martínez-Lacaci, Leticia Mayor-López, J. Bermejo, J. Luján, P. Carbonell, C. De Torre
Publikováno v:
European Journal of Cancer. 48:S232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3628b50241da180f4fd920439c538f6
https://doi.org/10.1016/s0959-8049(12)71582-4
https://doi.org/10.1016/s0959-8049(12)71582-4
Autor:
Lourdes Rocamora-Reverte, Isabel Martínez-Lacaci, Pablo Carbonell, Leticia Mayor-López, Mar Carballo-Santana, Fernando Carballo, P. Garcia-Morales, Silvina Grasso, Estefania Carrasco-Garcia, José A. Ferragut, Miguel Saceda, Elena Tristante
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 10, Pp 845-860 (2014)
Selumetinib (AZD6244, ARRY-142886) is a MEK1/2 inhibitor that has gained interest as an anti-tumour agent. We have determined the degree of sensitivity/resistance to Selumetinib in a panel of colorectal cancer cell lines using cell proliferation and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b64b4f7903e7683ea1a1bc736c6fd6d